Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (221-230 of 288) with videos related to

Pageof 29
Sort By:
Drug Design, Development and Therapy|July 5, 2022
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical PracticeMartina Ranzenigo, Nicola Gianotti, Laura Galli, et al.
Blood|August 15, 2002
Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapyMauro Malnati, Francesco Broccolo, Silvia Nozza, et al.
Medicine|July 19, 2016
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patientsFrancesca Ferretti, Alba Bigoloni, Laura Passeri, et al.
Antiviral Therapy|May 29, 2009
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patientsAlessandro Soria, Klaudia Porten, Jean-Calvin Fampou-Toundji, et al.
Lancet (London, England)|July 10, 2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trialAdriano Lazzarin, Thomas Campbell, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trialFrancesco Mazzotta, Sergio Lo Caputo, Carlo Torti, et al.
AIDS (London, England)|December 6, 2012
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trialsCalvin J Cohen, Jean-Michel Molina, Isabel Cassetti, et al.
Infection|May 21, 2020
HIV-1 recombinant forms in immigrants regularly residing in Milan, northern ItalySabrina Bagaglio, Caterina Uberti-Foppa, Caterina Sagnelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2004
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIVKathleen Squires, Adriano Lazzarin, José M Gatell, et al.
World Journal of Gastroenterology|October 28, 2016
TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotypeCaterina Sagnelli, Marco Merli, Caterina Uberti-Foppa, et al.
Pageof 29

Showing results (221-230 of 288) with videos related to

Sort By:
Pageof 29
Drug Design, Development and Therapy|July 5, 2022
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical PracticeMartina Ranzenigo, Nicola Gianotti, Laura Galli, et al.
Blood|August 15, 2002
Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapyMauro Malnati, Francesco Broccolo, Silvia Nozza, et al.
Medicine|July 19, 2016
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patientsFrancesca Ferretti, Alba Bigoloni, Laura Passeri, et al.
Antiviral Therapy|May 29, 2009
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patientsAlessandro Soria, Klaudia Porten, Jean-Calvin Fampou-Toundji, et al.
Lancet (London, England)|July 10, 2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trialAdriano Lazzarin, Thomas Campbell, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trialFrancesco Mazzotta, Sergio Lo Caputo, Carlo Torti, et al.
AIDS (London, England)|December 6, 2012
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trialsCalvin J Cohen, Jean-Michel Molina, Isabel Cassetti, et al.
Infection|May 21, 2020
HIV-1 recombinant forms in immigrants regularly residing in Milan, northern ItalySabrina Bagaglio, Caterina Uberti-Foppa, Caterina Sagnelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2004
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIVKathleen Squires, Adriano Lazzarin, José M Gatell, et al.
World Journal of Gastroenterology|October 28, 2016
TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotypeCaterina Sagnelli, Marco Merli, Caterina Uberti-Foppa, et al.
Pageof 29